Systematic Review

Vitamin D Levels in Early and Middle Pregnancy and Preeclampsia, a Systematic Review and Meta-Analysis

Kailun Hu 1,2,†, Chunxi Zhang 1,†, Panpan Chen 1, Dan Zhang 1,2,* and Sarah Hunt 3

1 Key Laboratory of Reproductive Genetics (Ministry of Education), Department of Reproductive Endocrinology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; hukailun@bjmu.edu.cn (K.H.); zhangcxi@zju.edu.cn (C.Z.); 12018523@zju.edu.cn (P.C.)
2 Key Laboratory of Women’s Reproductive Health of Zhejiang Province, Zhejiang University, Hangzhou 310006, China
3 Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC 3168, Australia; sarah.prema@hotmail.com
* Correspondence: zhangdan@zju.edu.cn; Tel./Fax: +86-0571-89991008
† These authors contributed equally to this work.

Abstract: Vitamin D (VitD) shows a beneficial role in placentation, the immune system, and angiogenesis, and thus, VitD status may link to the risk of preeclampsia. A meta-analysis was conducted to investigate the association between VitD status in early and middle pregnancy and the risk of preeclampsia. A total of 22 studies with 25,530 participants were included for analysis. Women with VitD insufficiency or deficiency had a higher preeclampsia rate compared to women with replete VitD levels (OR 1.58, 95% CI 1.39–1.79). Women with VitD deficiency had a higher preeclampsia rate compared to women with replete or insufficient VitD levels (OR 1.35, 95% CI 1.10–1.66). Women with insufficient VitD levels had a higher preeclampsia rate compared to women with replete VitD levels (OR 1.44, 95% CI 1.24–1.66). Women with deficient VitD levels had a higher preeclampsia rate compared to women with replete VitD levels (OR 1.50, 95% CI 1.05–2.14). Sensitivity analysis showed the results were stable after excluding any one of the included studies. In conclusion, our systematic review suggested that VitD insufficiency or deficiency was associated with an increased risk of preeclampsia.

Keywords: vitamin D; preeclampsia; pregnancy; systematic review; meta-analysis

1. Introduction

Preeclampsia is a multisystem disease during pregnancy, characterized by the new-onset of gestational hypertension and proteinuria. It occurs in around 3–8% of all pregnancies and is associated with increased maternal and fetal morbidity and mortality [1,2]. Maternal preeclampsia is also associated with a higher incidence of cardiovascular and kidney disease in the later life of the child [3–5]. Currently, delivery is the only curative therapy for preeclampsia, and pharmacological management is symptomatic treatment only. Therapies aimed at preventing preeclampsia therefore are a priority for ongoing investigation.

VitD deficiency is common during pregnancy, with a prevalence ranging from 8–70% depending on skin pigmentation and sunlight exposure [6–9]. Accumulating evidence suggests that VitD deficiency may be implicated in recurrent pregnancy loss, adverse obstetrical and neonatal outcomes [10,11]. More recently, attention has been paid to the potential association between VitD levels in pregnancy and the risk of preeclampsia. It has been postulated that increased VitD levels may improve the invasion of the human extravillous trophoblast, which is required for normal placentation [12]. Additionally, accumulating evidence suggested that VitD has a beneficial effect on endothelial repair and angiogenesis [13–15] and that VitD deficiency is associated with the pathogenesis of cardiovascular diseases and arterial hypertension [16,17]. Therefore, it is likely that VitD...
has a role in improving endothelial repair and angiogenesis and controlling blood pressure in preeclampsia [18]. Furthermore, the immunomodulatory properties of VitD may also reduce the risk of preeclampsia development [13,19,20]. Indeed, previous observational studies have demonstrated significant association between VitD deficiency and increased preeclampsia risk [21–23], whereas others suggest no association between maternal VitD deficiency and preeclampsia rate [11,24–26]. Overall, the epidemiological evidence from observational data is conflicting and most studies are limited by small sample sizes. Additionally, there is a lack of consensus regarding definition of VitD deficiency and the potential threshold level associated with preeclampsia risk. Although there have been several systematic review and meta-analysis papers related to the association of VitD with preeclampsia [27–30], some important studies were not included in these meta-analyses. Additionally, most studies included in these systematic reviews were case-control studies that investigated women in late pregnancy. Even when the association between VitD deficiency in late pregnancy and obstetric complications is detected, the prevention of these diseases by the modification of VitD status is too late.

In this systematic review, we aimed to determine the association between VitD levels in early or middle pregnancy (≤24 weeks) and the risk of pre-eclampsia.

2. Methods

2.1. Eligibility Criteria

The protocol of this systematic review was prospectively registered in PROSPERO (reference: CRD42021271154). We reported this systematic review according to the guideline of The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement 2020 [31]. We included all studies that investigated the association of VitD levels with the rate of preeclampsia. Because the detection of the association between VitD deficiency in early or middle pregnancy (rather than late pregnancy) and later obstetric complications may allow the prevention of these diseases by screening and modification of VitD status in early or middle pregnancy [24], we excluded studies if they investigated pregnant women over 24 gestational weeks. Reviews, case report studies, and study protocols were also excluded.

2.2. Search Strategy

Two authors (KLH and CXZ) independently searched the database of PubMed, EMBASE, Cochrane library, and Web of Science from January 1990 to July 2021. The search terms included “preeclampsia”, “vitamin D”, and “hypertensive disorder of pregnancy”. The detailed search terms could be seen in Table S1.

2.3. Selection Process

Two authors (KLH and CXZ) independently reviewed the titles and abstracts based on the predefined eligibility criteria. The full manuscripts were obtained when the titles and abstracts were considered to be related. Any disagreement between the two authors was resolved by a third review author. References from all included studies were checked to identify relevant articles not captured by the electronic searches.

2.4. Risk of Bias Assessment

Two reviewers (KLH and CXZ) independently assessed the quality of the included studies. Cohort and case-control studies were assessed according to The Newcastle-Ottawa Quality Assessment Scales [32]. Cross-sectional studies were assessed using the Agency for Healthcare Research and Quality (AHRQ).
2.5. Data Collection Process

Two reviewers (KLH and CXZ) independently extracted the data from included studies. If a study with multiple publications was found, the main report was used as the reference with additional details supplemented from other papers.

VitD levels were stratified into three groups according to Endocrine Society recommendations [9]: the replete level (>30 ng/mL or >75 nmol/L), the insufficient level (20–30 ng/mL or 50–75 nmol/L), and the deficient level (<20 ng/mL or <50 nmol/L). A few studies used 15 ng/mL (37.5 nmol/L) as the cutoff, and thus <15 ng/mL was considered as the deficient level in these studies. The primary outcome was preeclampsia, defined by the new-onset of gestational hypertension and proteinuria.

2.6. Synthesis Methods

The Stata 15.0 (StataCorp, College Station, TX, USA) was used to perform the meta-analysis using either the inverse-variance weighted model (fixed-effect) or the DerSimonian and Laird model (random-effect). Both were displayed in the forest plot, and the fixed-effect model was applied if no significant heterogeneity was identified ($I^2 < 50\%$), whereas a random-effect model was used if a significant heterogeneity was detected ($I^2 > 50\%$). The combined data was shown in a pooled odds ratio (OR) with a 95% confidence interval (CI). Publication bias was assessed by funnel plot asymmetry as well as Egger’s test. Sensitivity analysis was conducted by omitting each individual study in turn to explore the effect of a single study on the overall meta-analysis. Subgroup analysis was conducted according to the gestational weeks of pregnancy (early $\leq 14$ weeks, middle 15–24 weeks, early and middle not specified) and study design (case-control, cohort, cross-sectional). Statistical significance was set at $\alpha$ equals to 0.05.

3. Results

3.1. Characteristics of the Included Studies

Diagramatic representation of the review process is outlined in Figure S1. A total of 22 studies with a sample size of 25,530 were included for analysis [11,21,22,24–26,33–48]. The characteristics of the included studies are shown in Table 1. Study quality assessment were shown in Table S2 (case-control studies), Table S3 (cohort studies), and Table S4 (cross-sectional studies).

The included studies varied in publication date from 2007 to 2020. Eleven were case-control studies; eight were cohort studies and three were cross-sectional studies (Table 1). Sample sizes varied from 142 women to 5109 women. Six studies focused on women in early pregnancy and three studies included women in middle pregnancy (Table 1). While most studies defined insufficiency and deficiency at 30 ng/mL and 20 ng/mL, respectively, four studies used 15 ng/mL as the diagnostic cutoff [11,25,34,35] (Table S5). Nearly all studies used multivariable analysis; however, the number and type of potential confounders controlled for in the final analyses was not uniform between studies (Table S5).
<table>
<thead>
<tr>
<th>Studies</th>
<th>Study Type</th>
<th>Eligibility for Pregnant Women</th>
<th>Method of Measurement</th>
<th>Gestational Weeks of Sampling</th>
<th>Sample Size</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>[11]</td>
<td>Nested case–control</td>
<td>Women with multiple gestations, fetal anomalies, or maternal medical complications were excluded.</td>
<td>LCMS</td>
<td>15–21</td>
<td>266</td>
<td>Birmingham, America/52.3° N</td>
</tr>
<tr>
<td>[33]</td>
<td>Nested case–control</td>
<td>Women with multiple gestations, major congenital fetal anomalies, pregestational hypertension, kidney disease, diabetes mellitus, known thrombophilias, PCMD were excluded.</td>
<td>LCMS</td>
<td>15–20</td>
<td>241</td>
<td>Boston, America /52.58° N</td>
</tr>
<tr>
<td>[26]</td>
<td>Cohort</td>
<td>Women with abnormal liver function, chronic disease and tumor; severe infections, trauma or in perioperative, before 13 weeks of gestation, and women who take corticosteroids, drug abuse (including alcohol) were excluded.</td>
<td>ECLIA</td>
<td>16–20</td>
<td>1953</td>
<td>Guangzhou, China/23.1° N</td>
</tr>
<tr>
<td>[34]</td>
<td>Nested case–control</td>
<td>Women with adverse pregnancy outcomes were excluded</td>
<td>CLIA</td>
<td>10–14</td>
<td>5109</td>
<td>New South Wales, Australia/33.9°</td>
</tr>
<tr>
<td>[25]</td>
<td>Nested case–control</td>
<td>Women with GDM or give birth to SGA infants</td>
<td>LCMS</td>
<td>≤14</td>
<td>170</td>
<td>Boston, America /52.58° N</td>
</tr>
<tr>
<td>[22]</td>
<td>Nested case–control</td>
<td>Women who had aneuploidy screening at 20 weeks or less gestation and who subsequently delivered live born infants.</td>
<td>LCMS</td>
<td>≤20</td>
<td>2327</td>
<td>Pennsylvania, America/40.3°</td>
</tr>
<tr>
<td>[35]</td>
<td>Nested case–control</td>
<td>Nulliparous women aged 14–44 years, carrying singleton infants.</td>
<td>ELISA</td>
<td>≤22</td>
<td>265</td>
<td>Pennsylvania, America/40.3°</td>
</tr>
<tr>
<td>[36]</td>
<td>Nested case–control</td>
<td>Women with multiple gestations, calcium imbalance, hypertension, renal insufficiency, bone disease, lithium therapy, bowel malabsorption, or kidney stone disease were excluded.</td>
<td>RIA</td>
<td>≤15</td>
<td>402</td>
<td>six centers: one in Belgium and five in France</td>
</tr>
<tr>
<td>[21]</td>
<td>Nested case–control</td>
<td>Women with preexisting hypertension, missing essential outcome information (no gestational age at enrollment), or multiple gestations were excluded.</td>
<td>CLIA</td>
<td>≤20</td>
<td>2048</td>
<td>Quebec, Canada/46.5° N</td>
</tr>
<tr>
<td>[37]</td>
<td>Cross-sectional</td>
<td>Women with increased risks for intrauterine fetal growth restriction, hereditary thrombophilias, or acquired thrombophilias were excluded.</td>
<td>ECLIA</td>
<td>11–14</td>
<td>466</td>
<td>Almeria, Spain/36.8°</td>
</tr>
<tr>
<td>[38]</td>
<td>Cross-sectional</td>
<td>NA</td>
<td>CLIA</td>
<td>≤24</td>
<td>1382</td>
<td>Bern, Switzerland/46.5°</td>
</tr>
<tr>
<td>[39]</td>
<td>Cross-sectional</td>
<td>Women with PCMD, metabolic bone disease, liver, kidney, or gastrointestinal diseases and the use of vitamin D supplements.</td>
<td>ELISA</td>
<td>≤12</td>
<td>1000</td>
<td>Saudi Arabia/24.3°</td>
</tr>
<tr>
<td>[40]</td>
<td>Cohort</td>
<td>Nulliparous women with a low-risk singleton pregnancy. Pregnancies at increased risk of pre-eclampsia, SGA, or spontaneous preterm birth or medical history, known major fetal anomaly or abnormal karyotype were excluded.</td>
<td>LCMS</td>
<td>&lt;16</td>
<td>1754</td>
<td>Cork, Ireland/51.9° N</td>
</tr>
<tr>
<td>Studies</td>
<td>Study Type</td>
<td>Eligibility for Pregnant Women</td>
<td>Method of Measurement</td>
<td>Gestational Weeks of Sampling</td>
<td>Sample Size</td>
<td>Location</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>-------------------------------</td>
<td>-------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>[24]</td>
<td>Nested case–control</td>
<td>Maternal age between 18 and 39 years and not a current smoker or a user of other nicotine products. Women with PCMD, multiple pregnancies, vitamin D taken (&gt;2000 IU per day), fetal anomalies, or ART use were excluded.</td>
<td>CLIA</td>
<td>10–18</td>
<td>157</td>
<td>United States</td>
</tr>
<tr>
<td>[41]</td>
<td>Cohort</td>
<td>Women who regularly took 200 mg/d for vitamin C and/or 50 IU/d for vitamin E, or warfarin, or with fetal abnormalities, or with PCMD, or with repeated spontaneous abortion were excluded.</td>
<td>CLIA</td>
<td>12–18</td>
<td>697</td>
<td>Canada and Mexico</td>
</tr>
<tr>
<td>[42]</td>
<td>Cohort</td>
<td>Healthy, nulliparous women aged 18 years or older without PCMD or infertility treatment. Patients with predictors for hypovitaminosis D or a prior pregnancy that had progressed beyond the first trimester and resulted in a fetal loss were excluded.</td>
<td>ELISA</td>
<td>8–12</td>
<td>235</td>
<td>United States</td>
</tr>
<tr>
<td>[43]</td>
<td>Cohort</td>
<td>Women aged ≥ 18 years with either clinical or biochemical risk factors for pre-eclampsia</td>
<td>RIA</td>
<td>10–20</td>
<td>221</td>
<td>Canada/49° N</td>
</tr>
<tr>
<td>[44]</td>
<td>Cohort</td>
<td>Nulliparous women with a singleton pregnancy.</td>
<td>ELISA</td>
<td>&lt;17</td>
<td>2074</td>
<td>Amsterdam, the Netherlands</td>
</tr>
<tr>
<td>[45]</td>
<td>Cohort</td>
<td>Gestational age &lt; 24 weeks, resident in Rotterdam at the date of delivery, expected delivery date lies between June 2002 and July 2004</td>
<td>LCMS</td>
<td>&lt;24</td>
<td>3323</td>
<td>Rotterdam, the Netherlands</td>
</tr>
<tr>
<td>[46]</td>
<td>Cohort</td>
<td>Healthy pregnant women. Gravidae with serious nonobstetric problems are not eligible.</td>
<td>LCMS</td>
<td>&lt;20</td>
<td>1141</td>
<td>Camden, United States</td>
</tr>
<tr>
<td>[47]</td>
<td>Nested case–control</td>
<td>Suspected PE over 20 weeks of gestation between January 2010 and March 2013. Women who were diagnosed with PE before their presentation at the emergency department were not included.</td>
<td>CLIA</td>
<td>9–12</td>
<td>142</td>
<td>Oviedo, Spain</td>
</tr>
<tr>
<td>[48]</td>
<td>Nested case–control</td>
<td>After identifying women who developed preeclampsia, the control group was drawn by random selection and comprised 10 women delivered in each month of the year</td>
<td>CLIA</td>
<td>Mean (SD): 12 (3)</td>
<td>157</td>
<td>Malmo, Sweden /55°37’ N</td>
</tr>
</tbody>
</table>

Abbreviations: Premature rupture of membranes, PROM; preeclampsia, PE; gestational diabetes mellitus, GDM; small-for-gestational-age, SGA; diabetes mellitus, DM; preexisting chronic medical disease, PCMD; liquid chromatography–tandem mass spectrometry, LCMS; enzyme-linked immunosorbent assay, ELISA; electrochemiluminescence immunoassay, ECLIA; radioimmunoassay, RIA; chemiluminescent immunoassays, CLIA; assisted reproductive techniques, ART.
3.2. Replete Levels of VitD (≥30 ng/mL) versus Insufficient or Deficient Levels of VitD (<30 ng/mL)

A total of 17,719 pregnant women (n = 12,908 with replete levels of VitD and n = 4811 with insufficient or deficient levels of VitD) from 14 studies were included. Women with VitD < 30 ng/mL showed an increased preeclampsia rate compared to women with VitD ≥ 30 ng/mL (OR 1.58, 95% CI 1.39–1.79, I² = 34%, fixed-effect) (Figure 1). No publication bias was detected (Figure S2a, Egger’s test: p = 0.069). Sensitivity analysis demonstrated the results were stable after excluding any one of the included studies (Figure S3a). There was a trend toward an increased risk of preeclampsia in women with VitD < 30 ng/mL in both early pregnancy and middle pregnancy, but they were not statistically significant (early pregnancy: OR 1.29, 95% CI 0.93–1.79, I² = 0%, fixed-effect; middle pregnancy: OR 1.41, 95% CI 0.97–2.06, I² = 18%, fixed-effect) (Figure 1a). The pooled data from studies with a case-control design showed a significantly higher risk of preeclampsia in women with VitD < 30 ng/mL, but it was not seen in pooled data from cohort studies or cross-sectional studies (case-control: OR 1.80, 95% CI 1.56–2.09, I² = 0%, fixed-effect; cohort: OR 1.09, 95% CI 0.85–1.40, I² = 0%, fixed-effect; cross-sectional: OR 0.76, 95% CI 0.18–3.19, I² = 0%, fixed-effect) (Figure 1b).

Figure 1. Studies evaluating replete vitamin D levels versus insufficient or deficient vitamin D levels. (a): Studies were stratified by gestational weeks (early, middle, and early and middle not specified); (b): studies were stratified by the study design.

3.3. Replete or Insufficient Levels of VitD (≥20 ng/mL) versus Deficient Levels of VitD (<20 ng/mL or < 15 ng/mL)

A total of 23,217 pregnant women (n = 8084 with replete levels of VitD and n = 15,133 with insufficient or deficient levels of VitD) from 19 studies were included in this analysis. Women with VitD < 20 ng/mL had a higher preeclampsia rate as compared to women
with VitD $\geq 20$ ng/mL (OR 1.35, 95% CI 1.10–1.66, $I^2 = 57\%$, random-effect) (Figure 2).

No publication bias was detected (Figure S2b, Egger’s test: $p = 0.415$). Sensitivity analysis demonstrated the results were stable after excluding any one of the included studies (Figure S3b). There was a trend toward an increased risk of preeclampsia in women with VitD $< 20$ ng/mL in middle pregnancy but no significant difference in preeclampsia risk was seen in early pregnancy (early pregnancy: OR 0.85, 95% CI 0.62–1.18, $I^2 = 19\%$, fixed-effect; middle pregnancy: OR 1.59, 95% CI 0.87–2.92, $I^2 = 61\%$, random-effect) (Figure 2a). The pooled data from studies with a case-control or cohort design demonstrated significantly increased preeclampsia rates in association with VitD $< 20$ ng/mL, but it was not seen in pooled data from cross-sectional studies (case-control: OR 1.46, 95% CI 1.02–2.10, $I^2 = 77\%$, random-effect; cohort: OR 1.24, 95% CI 1.02–1.51, $I^2 = 0\%$, fixed-effect; cross-sectional: OR 1.08, 95% CI 0.49–2.35, $I^2 = 0\%$, fixed-effect) (Figure 2b).

![Figure 2. Studies evaluating replete vitamin D levels or insufficient versus deficient vitamin D levels. (a): Studies were stratified by gestational weeks (early, middle, and early and middle not specified); (b): studies were stratified by the study design.](image)

### 3.4. Replete Levels of VitD ($\geq 30$ ng/mL) versus Insufficient Levels of VitD (20–30 ng/mL or 15–30 ng/mL)

A total of 11,091 pregnant women ($n = 6856$ with replete levels of VitD and $n = 4235$ with insufficient or deficient levels of VitD) from 11 studies were included in this analysis. Women with VitD insufficiency were more likely to develop preeclampsia as compared to women who were VitD replete (OR 1.44, 95% CI 1.24–1.66, $I^2 = 23\%$, fixed-effect) (Figure 3). Publication bias was detected (Figure S2c, Egger’s test: $p = 0.005$). Sensitivity analysis showed the results were stable after excluding any one of the included studies (Figure S3c). A slightly increased risk of preeclampsia was seen in women with insufficient VitD levels...
in early pregnancy, but it was not seen in middle pregnancy (early pregnancy: OR 1.40, 95% CI 1.00–1.96, \(I^2 = 22\%\), fixed-effect; middle pregnancy: OR 1.21, 95% CI 0.83–1.76, \(I^2 = 0\%\), fixed-effect) (Figure 3a). The pooled data from studies with a case-control design showed a significantly higher risk of preeclampsia in women with insufficient VitD levels, but it was not seen in pooled data from cohort studies or cross-sectional studies (case-control: OR 1.59, 95% CI 1.35–1.88, \(I^2 = 0\%\), fixed-effect; cohort: OR 1.02, 95% CI 0.75–1.39, \(I^2 = 11\%\), fixed-effect; cross-sectional: OR 0.85, 95% CI 0.14–5.19) (Figure 3b).

3.4. Replete Levels of VitD (≥30 ng/mL) versus Insufficient Levels of VitD (20–30 ng/mL or 15–30 ng/mL)

A total of 11,091 pregnant women (\(n = 6856\) with replete levels of VitD and \(n = 4235\) with insufficient levels of VitD) from 11 studies were included in this analysis. Women with VitD insufficiency were more likely to develop preeclampsia as compared to women who were VitD replete (OR 1.44, 95% CI 1.24–1.66, \(I^2 = 23\%\), fixed-effect) (Figure 3). Publication bias was detected (Figure S2c, Egger’s test: \(p = 0.005\)). Sensitivity analysis showed the results were stable after excluding any one of the included studies (Figure S3c). A slightly increased risk of preeclampsia was seen in women with insufficient VitD levels in early pregnancy, but it was not seen in middle pregnancy (early pregnancy: OR 1.40, 95% CI 1.00–1.96, \(I^2 = 22\%\), fixed-effect; middle pregnancy: OR 1.21, 95% CI 0.83–1.76, \(I^2 = 0\%\), fixed-effect) (Figure 3a). The pooled data from studies with a case-control design showed a significantly higher risk of preeclampsia in women with insufficient VitD levels, but it was not seen in pooled data from cohort studies or cross-sectional studies (case-control: OR 1.59, 95% CI 1.35–1.88, \(I^2 = 0\%\), fixed-effect; cohort: OR 1.02, 95% CI 0.75–1.39, \(I^2 = 11\%\), fixed-effect; cross-sectional: OR 0.85, 95% CI 0.14–5.19) (Figure 3b).

3.5. Replete Levels of VitD (≥30 ng/mL) versus Deficient Levels of VitD (<20 ng/mL or <15 ng/mL)

A total of 8550 pregnant women (\(n = 4315\) with replete levels of VitD and \(n = 4235\) with deficient levels of VitD) from 11 studies were included in this analysis. Women with VitD deficiency were more likely to develop preeclampsia as compared to women with replete VitD levels (OR 1.50, 95% CI 1.05–2.14, \(I^2 = 64\%\), random-effect) (Figure 4). No publication bias was detected (Figure S2d, Egger’s test: \(p = 0.188\)). Sensitivity analysis showed the results were stable after excluding any one of the included studies (Figure S3d). A slightly increased risk of preeclampsia was seen in women with deficient VitD levels in middle pregnancy, but it was not seen in early pregnancy (early pregnancy: OR 0.96, 95% CI 0.61–1.51, \(I^2 = 0\%\), fixed-effect; middle pregnancy: OR 1.78, 95% CI 0.75–3.89, \(I^2 = 54\%\), random-effect) (Figure 4a). The pooled data from studies with a case-control design showed a significantly higher risk of preeclampsia in women with vitD deficiency, but it was not seen in pooled data from cohort studies or cross-sectional studies (case-control: OR...
1.99, 95% CI 1.24–3.18, \( I^2 = 71\% \), random-effect; cohort: OR 1.10, 95% CI 0.81–1.50, \( I^2 = 0\% \), fixed-effect; cross-sectional: OR 0.71, 95% CI 0.14–3.62, \( I^2 = 0\% \), fixed-effect) (Figure 4b).

VitD deficiency were more likely to develop preeclampsia as compared to women with replete VitD levels (OR 1.50, 95% CI 1.05–2.14, \( I^2 = 64\% \), random-effect) (Figure 4). No publication bias was detected (Figure S2d, Egger's test: \( p = 0.188 \)). Sensitivity analysis showed the results were stable after excluding any one of the included studies (Figure S3d). A slightly increased risk of preeclampsia was seen in women with deficient VitD levels in middle pregnancy, but it was not seen in early pregnancy (early pregnancy: OR 0.96, 95% CI 0.61–1.51, \( I^2 = 0\% \), fixed-effect; middle pregnancy: OR 1.78, 95% CI 0.93–3.41, \( I^2 = 54\% \), random-effect) (Figure 4a). The pooled data from studies with a case-control design showed a significantly higher risk of preeclampsia in women with VitD deficiency, but it was not seen in pooled data from cohort studies or cross-sectional studies (case-control: OR 1.99, 95% CI 1.24–3.18, \( I^2 = 71\% \), random-effect; cohort: OR 1.10, 95% CI 0.81–1.50, \( I^2 = 0\% \), fixed-effect; cross-sectional: OR 0.71, 95% CI 0.14–3.62, \( I^2 = 0\% \), fixed-effect) (Figure 4b).

Figure 4. Studies evaluating replete vitamin D levels versus deficient vitamin D levels. (a): Studies were stratified by gestational weeks (early, middle, and early and middle not specified); (b): studies were stratified by the study design.

4. Discussion

Our study included data from 22 observational studies and demonstrated an association between VitD deficiency or insufficiency and pre-eclampsia risks in early to middle pregnancy.

The pathogenesis of preeclampsia remains incompletely understood. It is proposed that incomplete remodeling of spiral arteries of the uterus during placentation induces limited perfusion and hypoxia of the placenta, with subsequent release of antiangiogenic factors into the maternal circulation [49–51]. These antiangiogenic factors, including tyrosine kinase-1 and soluble endoglin, can lead to endothelial damage and the clinical features that define preeclampsia [52,53]. In addition, a large amount of proinflammatory cytokines (IL-1\(\beta\), IL-6, and IL-8) are released from the neutrophils and monocytes in the decidua, leading to increased damage to the blood vessels [54,55]. A previous study demonstrated that increased VitD levels improved the invasion of the human extravillous trophoblast and thus proposed that VitD may exert a preventive effect on the development of preeclamptic disease [12]. Additionally, accumulating evidence have suggested that VitD plays a beneficial role in endothelial repair and angiogenesis [13–15] and that VitD deficiency is associated with the pathogenesis of cardiovascular diseases and arterial hypertension [16,17]. Therefore, VitD may have a role in augmenting endothelial repair and angiogenesis and
controlling blood pressure in preeclampsia [18] and its immunomodulatory properties may also reduce the risk of preeclampsia development [13,19,20].

The association between VitD deficiency during pregnancy and preeclampsia has been much investigated. Previous systematic reviews of observational studies have demonstrated that women with VitD deficiency (at cutoff 20 ng/mL) were more likely to develop preeclampsia [27,28,56,57]. However, the gestation at which the blood was collected are not fully discussed in these systematic reviews. In this review, we focused on the association of VitD levels in early and middle pregnancy, and VitD supplementation at these points in pregnancy may provide an opportunity for disease prevention or modification. Our review also included several new studies and important studies that have been omitted in previous meta-analyses. Moreover, most previous reviews have compared VitD levels $\geq 20$ ng/mL with VitD levels $< 20$ ng/mL, whereas our study compared VitD levels $\geq 30$ ng/mL, $<30$ ng/mL, and $<20$ ng/mL. Our study demonstrates that VitD levels higher than 30 ng/mL are associated with reduced preeclampsia risk when compared with VitD levels $<30$ ng/mL or $<20$ ng/mL, suggesting that women may benefit from the supplementation of VitD to a level of $\geq30$ ng/mL in early and middle pregnancy. This has been supported by previous observational studies and meta-analysis which demonstrated that VitD supplementation during pregnancy was related to a reduced rate of preeclampsia [58–62]. However, a systematic review of randomized trials found VitD supplementation did not significantly alter preeclampsia risk [63]. It should be noted that only three randomized trials with a total sample size of 654 were included in this systematic review [63], which may explain the inconsistency with other studies. A previous randomized trial suggested that VitD supplementation (4400 vs. 400 IU/d) in 10–18 weeks of pregnancy was not able to reduce preeclampsia risks [24]. However, VitD $\geq 30$ ng/mL at the trial entry were related a reduced rate of preeclampsia [24]. It should be noted that only 74% pregnant women has a replete VitD levels in the 4400 IU/d group in late pregnancy [24], which may explain the nonsignificant difference of preeclampsia incidence for VitD supplementation in early or middle pregnancy. Future trials should further investigate whether VitD supplementation to the replete levels during pregnancy is associated with reduced preeclampsia.

Our review has several strengths. We limited the gestational age of blood collection to early and middle pregnancy. Additionally, we compared replete, insufficient, and deficient VitD status and found that women who were VitD replete had lower rates of preeclampsia than women with VitD insufficiency or deficiency. We also conducted sensitivity analysis and demonstrated that our results were robust after omitting any one of the included studies.

This systematic review also has several limitations. The available studies were heterogeneous in terms of gestational weeks, study design, methods of VitD measurement, and skin characteristics. Additionally, we included observational studies; therefore, there is the potential that unrecognized confounders may have impacted our results. Recognizing the limitations of studies included in meta-analyses, however, forms a basis for future studies with more optimal design and methods to define the role of VitD in preeclampsia. Future RCTs should consider initiating VitD supplementation in early or middle pregnancy or even before pregnancy in women with VitD insufficiency or deficiency.

In conclusion, our systematic review demonstrated that VitD insufficiency (20–30 ng/mL) or deficiency ($<20$ ng/mL) was associated with an increased risk of preeclampsia. This raises the possibility that VitD supplementation in early or middle pregnancy may represent a risk-modifying therapy.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14050999/s1, Table S1: Search method for literature; Table S2: The Newcastle-Ottawa Scale (NOS) for assessing the quality of case-control studies; Table S3: The Newcastle-Ottawa Scale (NOS) for assessing the quality of cohort studies; Table S4: AHQR for assessing the quality of cross-sectional studies; Table S5: Vitamin D cutoff values and the calculated rate of preeclampsia in the included studies; Figure S1: Flowchart for study selection; Figure S2:
Funnel plot to assess publication bias. (a): Studies evaluating replete versus insufficient or deficient vitamin D levels; (b): Studies evaluating replete or insufficient versus deficient vitamin D levels; (c): Studies evaluating replete versus insufficient vitamin D levels; (d): Studies evaluating replete versus deficient vitamin D levels; Figure S3: Sensitivity analysis investigating the influence of a single study on the overall meta-analysis estimate. (a): Studies evaluating replete versus insufficient or deficient vitamin D levels; (b): Studies evaluating replete or insufficient versus deficient vitamin D levels; (c): Studies evaluating replete versus insufficient vitamin D levels; (d): Studies evaluating replete versus deficient vitamin D levels.

Author Contributions: Conceptualization, K.H.; methodology, K.H. and C.Z.; software, K.H., P.C. and C.Z.; validation, K.H., D.Z., S.H., P.C. and C.Z.; formal analysis, K.H.; investigation, K.H. and C.Z.; resources, K.H. and C.Z.; writing—original draft preparation, K.H. and C.Z.; writing—review and editing, K.H. and S.H. All authors have read and agreed to the published version of the manuscript.

Funding: This study is supported by the National Key Research and Development Program of China (2018YFC1005003), The National Key Research and Development Program of China (2021YFC2700601), The National Natural Science Foundation of China (No. 81974224), the Key Research and Development Program of Zhejiang Province (2021C03098), the National Key Research and Development Program of China (2021YFC2700402). All these fundings have no role in study design, collection, analysis, and interpretation of data, writing of the report, and the decision to submit the article for publication.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
10. Kiely, M.E.; Wagner, C.L.; Roth, D.E. Vitamin D in pregnancy: Where we are and where we should go. *J. Steroid. Biochem. Mol. Biol.* 2020, 201, 105669. [CrossRef]


38. Christoph, P.; Challande, P.; Raio, L.; Surbek, D. High prevalence of severe vitamin D deficiency during the first trimester in pregnant women in Switzerland and its potential contributions to adverse outcomes in the pregnancy. Swiss. Med. Wkly. 2020, 150, w20238. [CrossRef]